Guggenheim analyst Subbu Nambi lowered the firm’s price target on Castle Biosciences (CSTL) to $30 from $37 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for several companies in its Diagnostics and Life Sciences Tools coverage to reflect recent updates from the companies after meetings with management teams.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences management to meet with Stephens
- Castle Biosciences: Strong Buy Rating Driven by TissueCypher’s Promising Growth and Strategic Market Positioning
- Castle Biosciences’ 2024 Earnings: Growth Amid Challenges
- Castle Biosciences: Strong Growth Potential Despite Challenges, Buy Rating Affirmed
- Castle Biosciences price target raised to $37 from $36 at Baird